Forodesine: review of preclinical and clinical data (Q33676223)

28 July 2017

Forodesine: review of preclinical and clinical data (English)

1 reference

28 July 2017

5

Farhad Ravandi

1 reference

28 July 2017

4

Michael Keating

1 reference

28 July 2017

Aref Al-Kali

1

1 reference

28 July 2017

Varsha Gandhi

series ordinal

2

1 reference

28 July 2017

Mohamad Ayoubi

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

28 July 2017

1 reference

28 July 2017

6

1 reference

28 July 2017

8

1 reference

28 July 2017

1211-1217

1 reference

Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism of trimeric PNPs

28 July 2017

1 reference

Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity

21 January 2018

1 reference

Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)

21 January 2018

1 reference

Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines

21 January 2018

1 reference

Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir

21 January 2018

1 reference

Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts

21 January 2018

1 reference

Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955

21 January 2018

1 reference

Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents

21 January 2018

1 reference

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

21 January 2018

1 reference

Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates

21 January 2018

1 reference

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

21 January 2018

1 reference

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

21 January 2018

1 reference

Structural basis for inhibition of human PNP by immucillin-H

21 January 2018

1 reference

Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.

21 January 2018

1 reference

Pharmacology and mechanism of action of forodesine, a T-cell targeted agent

21 January 2018

1 reference

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application

21 January 2018

1 reference

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

21 January 2018

1 reference

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells

21 January 2018

1 reference

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.83

1 reference

28 July 2017

1 reference